Key result
Serum levels of miR-133a and miR-133b differentiated pediatric patients with supraventricular and ventricular arrhythmias from controls (AUC=0.8021, p=0.007 and AUC=0.8030, p=0.04, respectively).
Why the study?
Aberrant miRNA expression is implicated in arrhythmogenesis, but whether miR-1, miR-133a, and miR-133b can serve as diagnostic biomarkers in pediatric ventricular and supraventricular arrhythmias was unknown.
Can serum circulating miR-1, miR-133a, and miR-133b serve as diagnostic biomarkers for ventricular and supraventricular arrhythmias in pediatric patients?
Population
Pediatric patients with ventricular and supraventricular arrhythmias and arrhythmia-free controls
Comparison
Ventricular arrhythmia vs supraventricular arrhythmia vs arrhythmia-free controls
Authors
Loading...
Hypothesis-generating for miR-133a/b as pediatric arrhythmia biomarkers; prospective validation required before diagnostic adoption.
Case-Control
Can serum circulating miR-1, miR-133a, and miR-133b serve as diagnostic biomarkers for ventricular and supraventricular arrhythmias in pediatric patients?
Effect estimate: AUC 0.8021
p-value: p=0.007
Serum circulating miR-1, miR-133a, and miR-133b show potential as diagnostic biomarkers for supraventricular and ventricular arrhythmias in pediatric patients.
Moric‐Janiszewska et al. (2021) conducted a case-control in Ventricular and supraventricular arrhythmias. Serum circulating microRNAs (miR-1, miR-133a, and miR-133b) vs. Arrhythmia-free controls was evaluated on Differentiation between SVa patients and arrhythmia-free controls using miR-133a (AUC 0.8021, p=0.007). Serum levels of miR-133a and miR-133b differentiated pediatric patients with supraventricular and ventricular arrhythmias from controls (AUC=0.8021, p=0.007 and AUC=0.8030, p=0.04, respectively).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: